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1. Introduction 
 
Pneumocystis pneumonia (PCP) is an opportunistic fungal infection caused by 
Pneumocystis jirovecii (formerly known as P. carinii f. sp. hominis). It causes 
infection in immunosuppressed individuals, especially persons with Acquired Immuno 
Deficiency Syndrome (AIDS) (1,2). Since increased usage of immunosuppressive 
therapy for conditions such as organ transplantation, autoimmune disorders and 
malignancies, Pneumocystis has emerged as an important opportunistic pathogen in 
this category. It causes significant mortality and morbidity in immunocompromised 
patients, accounting for a mortality rate of 10 to 30% in AIDS patients, and 30 to 70% 
in non HIV infected patients with immunosuppression (3). 
 
History: 
Pneumocystis was first identified by Carlos Chagas in the lungs of rats and guinea 
pigs in 1909. He thought it could be a form of Trypanosoma cruzi, since he identified 
this organism in lungs of patients who had died of Trypanosoma infection. Antonio 
Carini also noted these cysts in rat lungs with trypanosomiasis, but he thought it might 
be a different organism. Three years later, in 1912 Pierre Delanoe and Marie Delanoe 
classified this organism under separate genus Pneumocystis, which was descriptive of 
the small but highly refractive and densely staining spherical cyst form of the microbe 
with predilection for lung and named the organism in honour of  Dr.Carini as 
Pneumocystis carinii, but they believed that it was a parasite. In 1942, it was reported 
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as the cause of pneumonitis in three infants in Netherland. Soon after Vanek and Otto 
Jirovec identified Pneumocystis as a cause of interstitial plasma cell pneumonia in 
malnourished infants during World War II and this pneumonia was referred to as 
Pneumocystis carinii pneumonia (PCP). Even though the causative organism was 
identified in early 19th century, only 80 cases were reported by 1973, as Pneumocystis 
was an uncommon cause of disease. But this scenario changed during the AIDS 
epidemic in the 1980s. Thereafter PCP became one of the common clinical diseases 
associated with immunocompromised patients (4–6). 
 
 Pnuemocystis was believed to be a protozoan for a period of 80 years from its 
discovery until 1988. Analysis of 16SrRNA revealed that Pneumocystis was a fungus 
not a protozoa (5). 
 
It was found that Pneumocystis infects only mammals and historically all the forms 
were referred to as P.carinii. Since it is species specific, the human form was renamed 
P.jirovecii in honour of Otto Jirovec in 1999, and the name P.carinii was reserved for 
rat form. Genetic sequence analysis of 18SrRNA of P.jirovecii (human derived) and 
P.carinii (rat derived) showed 5% difference between these two species. So species 
infecting different mammals are dissimilar. Even though there was a change in 
nomenclature, the abbreviation PCP remains to be used and the disease referred to as 
Pneumocystis pneumonia (7). 
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There are many challenges for laboratory diagnosis of PCP. Even though this is a 
fungus, this cannot be cultured in vitro in the laboratory. Therefore the laboratory 
diagnosis is based on visualisation of organism by microscopy in respiratory samples 
like induced sputum, broncho alveolar lavage (BAL), endo tracheal aspirate (ETA) 
and lung tissue. Stains commonly used to demonstrate this organism in the laboratory 
are Giemsa, toluidine blue-O, Gomori-Grocott methenamine silver, Diff-Quick and 
direct immunofluorescence assay (8). But sensitivity of the microscopic methods  vary 
from 60 to 92% for BAL samples and 35 to 78% for endo tracheal aspirates and 
induced sputum samples (9).  
 
Moreover following the introduction of highly active anti-retroviral therapy (HAART) 
for AIDS and co-trimoxazole prophylaxis for PCP, the incidence of PCP has come 
down. Thus, samples from suspected cases will have low burden of organisms which 
makes the diagnosis even more difficult by conventional microscopic methods (10).  
 
Molecular diagnosis by Polymerase chain reaction (PCR) with its low detection limits 
may be a good technique to detect the presence of P.jirovecii in the lung (11). There 
are many target genes for PCR such as dihydropteroate synthase (DHPS), 
dihydrofolate reductase (DHFR), internal transcribed spacer regions of the rRNA 
(ITS), mitochondrial large subunit rRNA (mtLSU rRNA), major surface glycoprotein 
(MSG), 5S rRNA, 18S rRNA, and cdc2, which were evaluated in many studies (12). 
Among these mtLSU rRNA target is being widely used for diagnosis as this gene has 
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multiple copies and is a highly conserved nucleotide sequence which gives high 
sensitivity and specificity (11).  
 
Colonization is an another important entity caused by Pneumocystis in 
immunocompromised patients, which means presence of low number of organisms 
without causing disease (4). Even though conventional PCR can detect low burden of 
the organism, it is not quantitative, as it cannot differentiate active PCP infection from 
colonization. A real time quantitative PCR (qPCR) can differentiate these two 
scenarios and can guide clinicians in diagnose PCP appropriately, especially in non 
HIV infected immunocompromised patients who are likely to have low burden of 
organisms (13). 
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2. Aim and Objectives of the Study: 
 
Aim: 
 
This study aims to evaluate a real-time quantitative PCR assay for diagnosing 
Pneumocystis jirovecii pneumonia in immunocompromised patients, compare 
these results with conventional microscopic methods and to correlate with clinical 
classification (composite standard) of PCP. 
 
Objectives: 
i. To evaluate a real-time quantitative PCR (qPCR) assay for diagnosis of 
Pneumocystis pneumonia (PCP) in immunocompromised patients. 
ii. To compare qPCR assay with conventional microscopic methods such as Giemsa 
staining and direct immunofluorescence assay (DFA) for diagnosis of PCP. 
iii.  To evaluate the Cost effectiveness of this new assay when compared to the 
conventional microscopic methods currently used for routine diagnostics. 
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3. Review of literature 
 
3.1. Epidemiology : 
 
3.1.1 Global burden: 
Before the AIDS epidemic in 1980, PCP was a rare disease among the immuno- 
compromised patients, accounting to 5%–25% in transplant patients, 2%–6% in 
patients with collagen vascular disease, and 1%–25% in patients with cancer (14). 
After 1980, P.jirovecii became the most common opportunistic infection among HIV 
infected persons, affecting 20 per 100 person-years for those with CD4+ cell counts 
<200 cells/μL. With the introduction of anti-pneumocystis prophylaxis in 1989, there 
was a decline in the incidence of PCP.  
In USA, the percentage of AIDS cases with PCP declined from 53% in 1989 to 42% 
in 1992. With the introduction of HAART, the incidence of PCP further decreased to 
3.4% per year from 1992 through 1995. The rate of decline was further declined to 
21.5% per year from 1996 through 1998 (14).  
In Europe, the EuroSIDA study showed that incidence declined from 4.9 cases per 
100 person-years before March 1995 to 0.3 cases per 100 person-years after March 
1998 (14).  
In developing countries, the incidence of PCP has declined with the advent of 
interventions such as anti-pneumocystis prophylaxis and HAART. These interventions 
are limited for developing regions like Sub Saharan Africa, where 23 million people 
are living with HIV infection. High PCP prevalence of about  27% reported from 
certain African countries (15). 
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3.1.2 The burden in India: 
There are very few studies/case reports published from India. One of the explanations 
could be the low sensitivity of available microscopic methods routinely used to 
diagnose Pneumocystis in most centres in India (16). 
In 1993, three cases of Pneumocystis were reported in AIDS patients from India.  A 
prospective study from North India done in August 1993 to December 1998 showed 
that prevalence of Pneumocystis in HIV infected and non HIV infected 
immunocompromised patients was 6.1% and 1.5% respectively (17). One cross 
sectional study done from January 2010 to October 2011in AIIMS, New Delhi 
showed a 15% prevalence of PCP in immunocompromised children, among these 45% 
children had renal disorders and were on immunosuppressants, though not on PCP 
prophylaxis (18). 
3.2. The Pneumocystis jirovecii 
 
3.2.1 Taxonomy: 
Pneumocystis jirovecii belongs to the phylum Ascomycota, class 
Pneumocystidomycetes, order Pneumocystidales, the family Pneumocystidacae, and 
to the genus Pneumocystis. The genus is descriptive of the small but highly refractive 
and densely staining spherical cyst form of the microbe that are extracellular, host 
obligate, host specific and typically restricted to the lung tissues of mammals.  
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Initially it was classified as a protozoan based on following criteria (7): 
i. Its morphology and host pathology. 
ii. Absence of chitin in cell wall which is a characteristic of fungus. 
iii. Presence of morphological forms which is characteristic of protozoa such as 
cyst and trophozoites. 
iv. Non response to anti-fungal drugs. 
v. Response to the drugs which is commonly used to treat protozoan infections 
such as co-trimoxazole and pentamidine. 
16srRNA sequencing of rat derived P.carinii in 1988 changed the history of 
Pneumocystis, reclassifying it into Kingdom Fungi. Other cloned genes of P.carinii 
which was helpful in this evolutionary relationship are dihydrofolate reductase 
(DHFR), thymidylate synthase (TS), β tubulin, α tubulin, the TATA-binding protein, 
P type cation- translocating ATPase, and the actin gene. Analysis of the above 
molecules placed P.carinii on its own branch between the ascomycetes and 
basidiomycetes of an evolutionary tree, but definitely within the fungal kingdom (5). 
3.2.1.1. Other species (19): 
i. Pneumocystis carinii – found in rats 
ii. Pneumocystis wakefieldiae – found in rats 
iii. Pneumocystis murina – found in mice 
iv. Pneumocystis oryctolagi – found in rabbits  
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3.2.2 Structure: 
Pneumocystis exists in three forms, the cyst, precyst (sporocyte), and trophozoite 
(trophic form) (19,20).  
Cyst: thick walled, round to ovoid or cub shaped structure, measures about 6 to 8µm 
size and contains up to eight pleomorphic sporozoites or spore. 
Precyst: smaller than mature cyst, measures 5 to 6µm size and oval in shape, contains 
rigid cell wall with 2 to 8 nuclei at varying levels of nuclear division.  
Trophozoite: extra cystic form, representing an excysted sporozoite and it is thin 
walled measures about 1 to 4µm size, commonly exists in clusters. 
3.2.2.1 Antigenic structure: 
Pneumocystis has many surface antigens that are glycosylated with mannose 
glycoproteins. These antigens are called glycoprotein A (gp A) or major surface 
glycoprotein (MSG) which has molecular masses ranging from 95 to 120 KDa and has 
an important role in pathogenesis by taking part in integration of Pneumocystis into 
host alveolar epithelial cells and evasion of the host defence mechanism. It is highly 
immunogenic. It has the ability to undergo antigenic variation by which it evades host 
immune response (6,21).                        
A second family of surface antigens i.e. subtilisin like serine proteases encoded by 
PRT1 (protease), also known as KEX multigene family was identified on the surface 
of Pneumocystis carinii. But only a single gene of KEX family was identified in 
P.jirovecii and P.murina and it is believed to take part in antigenic variation. 
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3.2.2.2. Cell wall: 
The fungal cell wall is made up of complex carbohydrates and structural proteins.     
β-1, 3-glucans are a major structural component of the Pneumocystis cell wall in both  
cystic and trophic forms. However there is little or no chitin in its cell wall. These 
glucan gives structural stability to the organisms in the infected lung as well as induce 
inflammatory response. Cholesterol is the dominant sterol present in Pneumocystis. 
Instead of ergosterol, the organism synthesizes distinct Δ7,C-24 alkylated sterols. 
Coenzyme Q10 (CoQ10) is the major ubiquinone homologue synthesized by the 
organism (6,21).  
                                  
Fig. 3.1 Showing fungal cell wall and antigenic structure (21) 
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3.2.3. Life cycle: 
Man acquires infection by inhalation of Pneumocystis from an individual with active 
PCP or transient subclinical colonization. There are two phases in the life cycle, 
asexual and sexual. In the asexual phase, multiplication is by simple binary fission of 
trophic form. In the sexual phase, haploid trophozoites conjugate together and form a 
diploid zygote or precyst which undergoes meiosis first, then mitosis to produce 
mature cyst or spore case which contains eight haploid intracystic bodies or a spore. 
Spores have different shapes being, either spherical or elongated and are released from 
the cyst through rents in the cyst wall (6,22). 
                                       
 
 
Fig. 3.2 Showing life cycle of Pneumocystis (Adapted from CDC DPDx – reference 22 
222222) 
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3.3. Pathogenesis of PCP: 
 
There is an abundant inflammation involving neutrophils and CD8 cells by 
Pneumocystis infection. This is the primary event in the pathogenesis of PCP which 
causes pulmonary injury characterised by diffuse alveolar damage and impaired gas 
exchange leading to respiratory failure which is the hallmark of the disease (21). 
Due to its small size, inhaled Pneumocystis escapes from upper respiratory tract and is 
deposited in the alveoli. The trophic form attaches tightly to type 1 alveolar epithelial 
cells and to a lesser extent to type 2 alveolar epithelial cells and initiates infection.  
The adherence of the organism produces lung damage and host response which leads 
to a massive influx of CD8 cells, neutrophils and macrophages along with local and 
systemic pro inflammatory cytokines (6,21). 
3.3.1 Host response to Pneumocystis infection: 
Host defences against Pneumocystis infection includes both innate and adaptive 
immunity. The innate immune system is comprised of alveolar macrophages, 
surfactant protein (SP)-A and SP-D (6). 
3.3.1.1 Macrophage activity: 
Pneumocystis is taken up by alveolar macrophages, primary resident phagocyte, 
through mannose receptors which interact with gpA/MSG on the surface of the 
organisms. There are also interactions between Pneumocystis β-glucans and the 
dectin-1 receptor. β-glucans in the cell wall of Pneumocystis stimulate macrophages to 
produce TNF, IL-8, and macrophage inflammatory protein 2 (MIP2). TNF recruits a 
massive amount of neutrophils, lymphocytes and monocytes for clearance of the 
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organisms. But neutrophils induce lung injury through the production of proteases, 
oxidants and cationic proteins. Even though TNF causes lung injury, it induces the 
generation of IL-8 from epithelial cells and interferon γ (IFN-γ) from lymphocytes, 
which further promotes inflammatory cell activation and recruitment during PCP. IL-8 
production is directly correlated with lymphocyte infiltration and decreased gas 
exchange in severe PCP. IL-8 level in broncho alveolar lavage fluid (BAL) could be a 
predictor of respiratory failure and death in PCP. IL-8 levels in BAL fluid in non HIV 
infected immunocompromised patients with PCP is higher compared to HIV infected 
patients with PCP and this level directly proportionate to the oxygenation index. 
Impaired macrophage function in patients with AIDS and patients with malignancies 
suppresses  Pneumocystis clearance (21). 
3.3.1.2. Surfactant proteins activity: 
SP-A accelerates the interaction between alveolar macrophages and Pneumocystis, 
thus phagocytosis also. By contrast the organisms can also escape the host defence 
mechanism as SP-D mediates aggregation of the organisms into large conglomerates 
which is poorly phagocytosed by macrophages. During PCP, production of surfactant 
phospholipids is reduced which leads to stiffer lung which is difficult to ventilate (21). 
3.3.1.3. Lymphocyte response during PCP: 
Both CD4 and CD8 T lymphocytes play important role in pathogenesis. CD4 cells 
have crucial role in host defence mechanism by providing memory function which 
recruit additional effector cells like monocytes and macrophages which are 
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responsible for elimination of the organism. So there is an increased risk of infection 
if CD4 cell count are less than 200/µl (21). 
3.4. Clinical manifestations of PCP: 
 
3.4.1. Risk factors: 
PCP is an opportunistic fungal infection occurs in immunosuppressed individuals. 
Immunosuppression is mainly due to either underlying diseases/conditions or its 
treatment. Risk groups can be classified into HIV infected and non HIV infected 
patients since clinical features and risk factors are quite different for both groups (23). 
3.4.1.1. Risk factor for HIV infected patients: 
The most common and only one risk factor in HIV infected patients are CD4 T 
lymphocyte counts. PCP is common if CD4 count is less than 200 cells/µl. 
3.4.1.2. Risk factors for non HIV infected patients: 
Diseases or conditions which increases the susceptibility for PCP in non HIV infected 
patient groups are following (23); 
i. Haematological malignancies 
ii. Solid organ tumour 
iii. Organ transplantation or haematopoietic stem cell transplantation (HSCT) 
iv. Connective tissue disorders on immunosuppression. 
Treatment related risk factors are use of following (23); 
i. Corticosteroids 
ii. Purine analogues 
16 
 
iii. Anti-CD52 and anti-CD20 monoclonal antibodies 
iv. Calcineurin inhibitors 
v. TNF-α antagonists  
3.4.2. Clinical manifestations in HIV infected patients: 
In HIV infected patients, PCP has a slow progressive course of about 2 weeks to 2 
months. Clinical manifestations include subtle onset of dyspnoea, fever, non-
productive cough and chest discomfort. Respiratory examination in acute cases reveal 
tachypnoea, tachycardia, and diffuse dry rales. Oral thrush is a commonly observed 
condition in these group of patients. 
Bilateral diffuse symmetrical lung infiltrates extending from the perihilar region as 
butterfly pattern is a classic finding in Chest radiography. This pneumonia is referred 
to as interstitial plasma cell pneumonia. 
                
               
Fig. 3.3 Chest X-ray showing bilateral 
lung infiltrates (Adapted from reference 6) 
 
Fig. 3.4 HRCT showing typical ground 
glass opacity (Adapted from reference 6) 
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In mild cases of PCP Chest radiography may be normal. Atypical radiographic 
presentations such as nodules, blebs, cysts, unilateral infiltrates, lymphadenopathy, 
effusion and pneumothorax may also occur. In such cases high resolution computed 
tomography (HRCT) will be helpful. It shows ground glass opacity (GGO). Impaired 
oxygenation or hypoxaemia is a common abnormality seen in PCP patients. Severity 
of disease can be classified into mild, moderate, and severe, based on alveolar-arterial 
oxygen difference. Serum lactate dehydrogenase (LDH) levels are often high, 
reflecting lung injury, though nonspecific (24). 
3.4.3. Clinical manifestations of PCP in non-HIV patients: 
In contrast to HIV infected patients, PCP in non-HIV infected immunocompromised 
presents with an abrupt onset of respiratory insufficiency, despite harbouring low 
levels of the organism. This difference is mainly due to aberrant immune response 
seen in this group of patients. Mortality rate is high (30% to 60%) in non HIV infected 
patients compared to 10 to 20% in HIV infected patients (23). 
3.5. Pneumocystis colonization: 
 
The detection of Pneumocystis organisms or their DNA in respiratory samples of 
individuals without any signs and symptoms of PCP,  is referred to as Pneumocystis 
colonization or carriage or subclinical infection (25,26). 
3.5.1. Epidemiology of Pneumocystis colonization: 
Exposure to Pneumocystis happens in early childhood. This was supported by a 
Spanish seroprevalence study in 233 healthy children, which showed overall 
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seroprevalence rate of  73%, with an age-related increase from 52% at 6 years to 66% 
at 10 years and 80% at 13 years (27).   
Prevalence of Pneumocystis colonization in HIV infected individuals varies from 14% 
to 69%. This wide variation is may be due to several reasons - difference in samples 
used/the population tested or the sensitivity of test used in various studies (26). 
 In non HIV infected immunosuppressed individuals, prevalence rate accounts for 
35% to 60% (25). Pneumocystis colonization can also occur in patients with chronic 
lung diseases like COPD, chronic bronchitis, cystic fibrosis, lung cancer, interstitial 
lung disease of about 2.6% to 35% (26).  
3.5.2. Consequences of Pneumocystis colonization: 
The true clinical significance of Pneumocystis colonization is not known. However 
some authors have suggested that it can lead to active PCP in susceptible hosts as well 
as acts as a reservoir for transmission of disease. It may induce pulmonary 
inflammation and mild lung injury as suggested by association with chronic lung 
disease and could be an important cofactor for progression of lung disease (26). 
3.6. Laboratory diagnosis: 
 
The role of the laboratory in the diagnosis of any infection depends on the clinical 
condition of the patients. In patients with HIV infection presenting late in their illness 
with pneumonia, the clinical presentation alone can be diagnostic and laboratory 
diagnosis of PCP may be unnecessary. However, in patients with early disease, 
including those receiving prophylactic chemotherapy, or those who are not obviously 
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immunocompromised, the laboratory diagnosis of PCP is critical for correct 
management. 
The laboratory diagnosis of PCP is challenging as in vitro cultivation is not successful 
and the diagnosis is mainly dependent on direct demonstration of the organism in 
respiratory specimen. 
3.6.1. Samples: 
Respiratory samples which are routinely used for diagnosis of PCP are classified as 
follows: 
 
 
 Induced sputum is obtained after nebulization with 3 to 5% hypertonic saline 
for 10 to 20 minutes and the material is mainly from central proximal airway. 
o The advantage of induced sputum is that it is non-invasive, repeatable 
and inexpensive (28).   
Respiratory samples
Non invasive
1. Induced sputum
2. Endotracheal arpirate
Invasive
1. Broncho alveolarlavage
2. Transbronchial biopsy
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o Disadvantage is that it has only a yield of 55%, when compared to other 
invasive samples like BAL and trans bronchial biopsy which have a 
yield of 79% and 90% respectively (29).  
 Broncho alveolar lavage (BAL) is obtained through bronchoscopy and the 
material is from the peripheral airways and alveolar compartment (29). 
 
3.6.2. Classification: 
Laboratory diagnosis of Pneumocystis jirovecii can be classified as follows: 
 
 
 
 
 
Lab diagnosis
Direct method
Direct visualisation of 
organism by 
microscopy using 
various staining 
techniques
Molecular methods
Indirect method Serological tests
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3.6.2.1. Direct methods: 
Direct method comprises different staining techniques which stain different 
morphological forms of P.jirovecii, and classified as follows: 
 
 
Grocott-Gomori methenamine silver (GMS) staining: 
Principle: 
It is a silver staining method which stains the cyst wall. The principle of this stain is 
that the mucopolysaccharide components of the fungal cell wall are oxidized to 
release aldehyde groups. The aldehyde groups then react with the silver nitrate, 
reducing it to a metallic silver, rendering them visible. Gold salt stabilizes the 
complex and sodium thiosulfate wash will remove the excess silver. 
Direct methods
Stains for cyst wall
Grocott-Gomori methenamine silver (GMS)stain
Toludine Blue O stain (TBO)
Calcoflour white stain (CFW)
Stains for trophozoites
Giemsa stain 
Diff-Quik stain (DQ)
Papanicolaou stain
Stain for both cyst and trophozoite
Direct immunofluorescent antibody test (DFA)
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Procedure (30) 
 Slide is microwaved for 40 seconds in a 10% chromic acid solution. 
 It is then rinsed with water followed by 1% sodium metsbisulfite for 30 
seconds. 
 The slide is kept in a Coplin jar containing 50ml of working methenamine 
solution and microwaved for 65 seconds.  
 The slide is rinsed with water and treated with 1% gold chloride for 2 to 5 
seconds. 
 It is then rinsed with water and treated with 5% sodium thiosulfate. 
 Counter staining is carried out with light green working solution, following 
which it is rinsed in xylene  
 Coverslip is applied and examined under light microscopy. 
Appearance: 
Cysts are distinctly stained with black or brown colour with a typical cup shaped 
morphology against a green background. In some instances, cyst wall thickening gives 
“double comma” appearance. Dark brown to black staining of the folds gives a 
“crinkled raisin-like” appearance. The intra cystic daughter form cannot be visualised, 
thus empty cysts appear similar to cysts with all eight spores (19).                                                                                                                
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 Advantages (19) 
i. Cysts can be easily detected 
ii. Host cells are not stained  
Disadvantages (29,31) 
i. Trophozoites cannot be identified 
ii. Expensive  
iii. Time consuming  
iv. Requires skilled personnel 
v. High background staining  
 
Toludine blue O (TBO) staining: 
Principle: 
This is a cyst wall staining method, based on the principle of “metachromasia”. 
Toludine blue is an acidophilic metachromatic dye, has affinity for tissues with high 
content of DNA and RNA, and DNA stains purple with a blue background (32). 
Fig. 3.5 showing cysts of Pneumocystis 
jirovecii in BAL, stained with GMS stain 
(adapted from reference 30) 
24 
 
Procedure (33) 
 The smear is treated with sulfation reagent (combination of glacial acetic acid 
and sulphuric acid) in a Coplin jar for 10 minutes. 
 It is then rinsed in cold running tap water for 5 minutes. 
 Slide is kept in toluidine blue O stain for 3 minutes. 
 The smear is decolourised with 95% ethyl alcohol and absolute alcohol for 10 
seconds each. 
 Coverslip is applied with permount. 
 The slide is examined under 20X, and 40X objective in light microscopy. 
Appearance: 
Here, cysts appear similar to those stained by the GMS stain, but that the colour of the 
cyst is light purple or lavender in colour against blue background. This will stain other 
yeasts and fungal elements also. 
 
Advantages (19) 
i. Cysts can be easily detected 
ii. Host cells are not stained 
iii. Faster than silver staining method (20 minutes)  
Fig. 3.6 showing cysts of Pneumocystis 
jirovecii in BAL, stained with TBO stain 
(adapted from reference 31) 
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Disadvantages (19,29) 
i. Mixture of sulphuric acid and glacial acetic acid is required for the procedure. 
As both are noxious substances, requires a fume hood  
ii. Yeasts can be mistaken for Pneumocystis cyst 
iii. Stains only cysts, other forms cannot be identified  
Calcofluor white (CFW) staining: 
Principle: 
Calcofluor white is a fluorescent whitener or fluorescent brightener. It has an active 
ingredient, Cellufluor, which has the ability to bind non-specifically with cellulose 
and chitin of the fungal cell wall. When exposed to UV light, it fluoresces. 
Procedure (30) 
 One drop of Calcofluor stain is added to the sample on a clean glass slide. 
 Coverslip is applied and is kept in dark humidifying chamber at room 
temperature for 10 minutes  
 Examined under a fluorescence microscope  
Appearance: 
The cyst is stained brightly against a dark background, often with characteristic 
“double parenthesis” or “body within the cyst” appearance. It produces a yellow green 
or apple green fluorescence at 420 to 490 nm with suppression filter of 515 nm, and a 
fluorescent blue colour at 340 to 380 nm with suppression filter of 430 nm (19,34). 
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Advantages: 
i. Technically simple procedure 
ii. Inexpensive 
iii. Cysts fluoresce brightly. 
Disadvantages: 
i. Fluorescence microscope is required 
ii. It will stain other fungal elements also and requires expertise  
iii. Forms other than cysts cannot be visualised. 
 
Giemsa staining: 
Principle: 
Giemsa stain is a type of Romanowsky stain, containing both eosin Y (acidic dye) and 
oxidised methylene blue, azure B (basic dye). Eosin Y stains basic organelles of the 
cell such as cytoplasm, whereas azure B stains acidic organelles such as nucleus. 
 
 
Fig. 3.7 showing cysts of Pneumocystis 
jirovecii in BAL, stained with Calcofluor 
white (adapted from reference 34) 
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Procedure: 
 The smear is fixed with methanol 
 The slide is immersed in a Petri dish containing Giemsa stain for 30 minutes. 
 The slide is washed with tap water  
 Examined under an oil immersion objective. 
Appearance: 
This does not stain the cyst wall, but stains nuclei of all morphological forms in the 
life cycle a reddish purple, while the cytoplasm stains light blue. Clusters of trophic 
forms give “mat appearance”. The cyst wall appears as a clear circumscribed zone 
around a reddish purple nuclei. This will stain lung cells also, but the nuclei appears 
larger and deep reddish purple (19).  
 
Advantages: 
i. Simple technique, that can be adapted in all kind of laboratories 
ii. Inexpenisve 
iii. Stains all stages of Pneumocystis life cycle 
iv. Sensitivity is expected to be high because of trophic forms which are ten times 
more than cysts, while other stains do not detect the former. 
Fig. 3.8. Showing trophic forms of 
Pneumocystis jirovecii in BAL, stained with 
Giemsa stain (adapted from CDC DPDx) 
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Disadvantages: 
i. Requires an experienced person to distinguish between Pneumocystis trophic 
cluster from host cells 
ii. High background staining 
Diff-Quik staining: 
It is a modifed Wright Giemsa stain or rapid Giemsa like stain. It is a rapid staining 
technique that takes very few minutes to perform. The principle is same as the Giemsa 
stain (35). 
Procedure: 
 The smear is air dried, and dipped in fixative (Fast green in methanol) for  30 
seconds 
 It is then dipped in Diff-Quik stain I (Eosin G in phosphate buffer) for 30 
seconds  
 Counterstaining is carried out with Diff-Quik stain II (Thiazine dye in 
phosphate buffer) for 30 seconds.  
 It is then rinsed with tap water and dehydrated in absolute alcohol. 
 Mounted under a light microscope. 
Appearance: 
The Diff-Quik staining is a very good method for detection of alveolar casts. The 
Presence of alveolar casts in BAL indicates active Pneumocystis infection. Thus, Diff-
Quick staining is useful particularly for this sample. 
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Advantage and disadvantages are same as Giemsa staining, except that it takes less 
time i.e. less than five minutes to perform staining. 
Papanicolaou (Pap) staining: 
It is a routine cytopathological staining method. Since it can stain the trophic form, it 
is used to stain Pneumocystis.  
Appearance: 
It stains clusters of extra cellular organisms a green colour, but thick clusters of 
organisms appear bicolored. 
Advantage: 
i. Stain is commonly available in all cytopathological lab 
Disadvantages: 
i. Trophic forms are stained faintly 
ii. Better stains are available  
Fig. 3.9 Showing alveolar casts of amphophilic, 
amorphous material in honeycomb pattern of 
Pneumocystis jirovecii stained by Diff-Quik stain, 
20x (adapted from ref: 32) 
 
 
 
 
 
() 
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6.2.1.7. Direct immunofluorescent antibody test: 
Principle: 
It is an antigen detection method by direct immunofluorescence technique. Here 
fluorescein isothiocyanate (FITC) labelled monoclonal antibodies are used against a 
family of surface glycoprotein antigen present on cyst wall, trophozoite and sporozoite 
to identify all forms of Pneumocystis.  
Procedure: 
 The smear is fixed with acetone 
 Detection reagent containing FITC labelled monoclonal antibodies are added to 
sample well. 
 The slide is incubated at 37°C in moist chamber for 30 minutes. 
 It is then rinsed with water. 
 Mounting fluid is added and cover slip is applied 
 Examined under a fluorescence microscope under 20X and 40X magnification. 
 
 
Fig.3.10 Showing trophic form of 
Pneumocystis jirovecii in BAL, stained with 
Pap stain (adapted from reference 30) 
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Appearance: 
It stains the cyst, trophozoite and other forms also and fluoresces apple green. 
Contents of the cyst are unstained and stand out black or dull. Some times folds of 
cyst wall are prominent and gives a crinkled, raisin like appearance. Staining of 
clusters gives a diffuse green glow, within which trophic forms appear as polygons or 
small spheres (19).  
 
Advantages: 
i. Highly sensitive and specific, since it can detect all forms 
ii. Very simple and rapid technique 
Disadvantages: 
i. Requires fluorescence microscope 
ii. Reagents are costly, cannot be implemented in resource poor laboratories 
iii. Shelf life of reagent is short. 
3.6.2.2. Molecular methods: 
Microscopic methods have many challenges. Their sensitivity and specificity is 
dependent on various factors like, type of specimen either invasive or non-invasive, 
burden of organisms in the specimen examined, staining methodology, use of 
Fig.3.11 Showing typical honey comb pattern 
stained with DFA (adapted from CDC DPDx) 
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prophylactic treatment before collection of specimen and the number of specimens 
examined from an individual (36).  
Induced sputum is routinely employed as it is non-invasive and involves a simple 
procedure. It has low number of organisms compared to other invasive samples like 
BAL and trans-bronchial biopsy.  
The low burden of organisms seen in patients who had taken prophylactic or 
therapeutic treatment before collection of sample. This further reduces the sensitivity 
of microscopic methods. 
Many studies compared the different staining techniques giving variable rate of 
sensitivity and specificity for each staining as well as each type of samples. So we 
cannot rely on a single microscopic staining method for diagnosis. 
Molecular methods using polymerase chain reaction (PCR) might be an alternative 
technique to overcome the disadvantages of staining techniques. The first 
conventional PCR for Pneumocystis was developed by Wakefield et al in 1990 (37). 
Many PCR assays have been developed in the past two decades, using different targets 
such as mtLSU rRNA, DHPS, DHFR, ITS, 5S rRNA, 18S rRNA, and cdc2. Among 
these, the PCR assays targeting mitochondrial 23SrRNA region in mtLSU rRNA 
gene, showed high sensitivity and specificity  (38). 
Further, sensitivity of conventional PCR was increased by nested PCR. Contamination 
is a significant problem with nested PCR, as double runs are performed in an open 
system. Thus, high false positivity rate and low specificity is seen with this technique 
(39). 
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Although conventional PCR was able to detect low burden of organisms, its inability 
to discriminate colonization from active infection made researchers move towards the 
real time quantitative PCR (qPCR). The first quantitative PCR for Pneumocystis was 
developed by Larsen et al. in 2002 (40). After that many studies done on qPCR 
showed that colonization has significantly lower number of organisms than active 
PCP infection (41–44).  
Advantages of real time PCR (39): 
i. Rapid: When compared to conventional PCR, as there is no post PCR 
processing step. 
ii. Less contamination: Since amplification and detection occurs in a closed tube. 
iii. Quantification of the amplified product: As the analysis is performed in the 
early log phase of product accumulation. 
6.2.3. Serological methods: 
Serological tests available for diagnosis of Pneumocystis are; 
i. Beta-D glucan assay 
ii. Serum lactate dehydrogenase (LDH) level 
iii. S-adenosylmethionine level 
iv. KL-6 level 
v. Antibody detection by ELISA 
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Beta-D glucan assay: 
1, 3 β-D glucan (BG) is a major structural component of cell wall of all pathogenic 
fungi including P.jirovecii. There are four kits available to perform serum β-D glucan 
level. The Fungitell BG assay is a chromogenic kinetic test (Associates of Cape Cod, 
East Falmouth, MA) was approved by the U.S. Food and Drug Administration in 2003 
for presumptive identification of invasive fungal infection (IFI) (45). These studies 
showed that serum β-D glucan levels are elevated in active PCP cases as well as 
decreased with effective anti-pneumocystis treatment. BG assay has very good 
sensitivity and specificity of 92% and 86% respectively with 31.1pg/ml as a cut off 
(46).  Specificity is moderate, as β-D glucan is present in other fungi also. Onishi A et 
al in a systematic review recommends that (47); 
i. This BG assay can be used as a screening test for PCP because it has high 
sensitivity for PCP rather than IFI, which will avoid the need of invasive 
samples for microscopy. 
ii. As this assay has moderate specificity, if test comes positive, factors like other 
fungal infections, use of intravenous amoxicillin clavulanic acid, treatment of 
patients with immunological preparations (albumins or globulins), use of 
cellulose membranes and filters made from cellulose in haemodialysis, and use 
of cotton gauze swabs/packs/pads and sponges during surgery should be ruled 
before taken it as a clinically significant result. 
iii. It is useful in non-HIV infected patients also as there are no significant 
difference in the results between HIV positive and negative patients. 
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Serum lactate dehydrogenase (LDH) level: 
LDH is a non-specific marker for the diagnosis of PCP. It is a cytoplasmic enzyme, 
present in all organs. Extracellular appearance of LDH indicates organ damage. In 
PCP it is well correlated with the degree of lung damage.  
Though it has 100% sensitivity in HIV positive PCP patients, it has a limited 
specificity of 45%, as LDH can be elevated in other disorders like hepatic, 
hematologic, and neoplastic disorders. As it has low sensitivity of 67% in non-HIV 
infected immunocompromised patients, serum LDH level cannot be used as a 
screening test (48,49). 
 
Serum S-adenosylmethionine level: 
S-adenosylmethionine (AdoMet) is a universal methyl donor, synthesised from 
methionine and ATP by S-adenosylmethionine synthetase enzyme. It is an important 
intermediate involved in methylation reaction and polyamine synthesis.  
Pneumocystis obtain AdoMet from host cell as they lack enzymes to synthesise it. 
Hence there is a decreased level of serum AdoMet in PCP patients. (50, 51). Though it 
is a sensitive and specific marker for PCP in HIV infected individuals, it has limited 
value in non-HIV infected immunocompromised patients (51). 
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Serum KL-6 level: 
KL-6 is a mucin like glycoprotein present on type II pneumocytes and bronchiolar 
epithelial cells. Serum KL-6 levels are elevated in interstitial lung disease and severe 
lung disease. Many authors have suggested that elevated KL-6 level could be a 
serological marker for PCP. But these levels are elevated in other non-fungal 
respiratory infections like Legionella pneumonia, severe pulmonary tuberculosis, and 
RSV bronchiolitis also. Therefore it cannot be used as a specific marker for 
Pneumocystis as β-D glucan (52). 
 
Antibody detection by ELISA: 
In general serum antibody detection has limited value in immunocompromised 
patients, especially in HIV positive patients (53). Pneumocystis specific IgG can be 
detected by ELISA using recombinant major surface glycoprotein antigen. As healthy 
individuals also have significant levels of antibody, this cannot be used for routine 
diagnosis, but may be used for epidemiological studies (54). 
 
3.7 Treatment:  
 
Treatment of patient is based on the clinical severity of the disease. 
The PCP is classified into mild, moderate and severe based on following criteria 
(Table 3.1) (55): 
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Table. 3.1 Classification of PCP 
 Mild Moderate Severe 
Symptoms and 
signs 
Dyspnoea on 
exertion with or 
without cough and 
sweats 
Dyspnoea on 
minimal exertion 
and occasionally 
at rest with 
cough and fever 
Dyspnoea and 
tachypnoea at rest 
with persistent cough 
and fever 
Arterial oxygen 
tension at rest 
(PaO2) 
 
>82.7 mmHg 
 
60 – 82.7 mmHg 
 
< 60 mm Hg 
Arterial oxygen 
saturation at rest 
 
>96% 
 
91 – 96% 
 
<91% 
Chest radiography Normal or minor 
perihilar 
shadowing 
Diffuse 
interstitial 
infiltration 
Extensive interstitial 
infiltration with or 
without diffuse 
alveolar shadowing 
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Table 3.2 shows the summary of first and second line anti-PCP treatment (for 21 days) 
(56). 
 
Table. 3.2 Anti-PCP treatment 
Disease 
classification 
First line drug Second line drugs TMP-SMX failure 
Moderate to 
severe 
Trimethoprim-
sulfamethoxazol
e (TMP-SMX) 
intravenously 
four times daily 
1. Clindamycin-
Primaquine orally 
2. Pentamidine 
intravenously 
1. Substitute or 
add 
intravenous 
Pentamidine 
2. Substitute 
Trimetrexate 
+ leucovorin 
Mild to 
moderate 
TMP-SMX 
orally four times 
daily 
1. Nebulised 
Pentamidine  
2. Clindamycin-
Primaquine orally 
3. Atovoquone orally 
4. Dapsone + TMP 
orally 
1. TMP-SMX 
intravenously 
four times 
daily 
2. Pentamidine 
intravenously 
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Prophylaxis: 
Prophylactic treatment is recommended in HIV positive patients with CD4 counts less 
than 200/mm3. The drug of choice is Trimethoprim Sulphomethoxazole (TMP-SMX) 
one tablet daily (TMP 80 mg/ SMX 400 mg) or two tablets thrice weekly, which will 
give protection for toxoplasmosis also. Alternatives are nebulised Pentamidine, 
Atovoquone, and Dapsone-TMP combination (24). 
In non HIV immunocompromised patients, prophylaxis with TMP-SMX should be 
considered carefully, as it causes hepatotoxicity and bone marrow depression. 
Prophylaxis is recommended for renal transplantation patients because 5 to 33 % of 
mortality rate was reported due to PCP without prophylaxis. It is also recommended in 
Wegener’s granulomatosis patients as incidence of PCP is more in these group of 
patients (23). 
Emerging resistance 
TMP-SMX is an effective drug for treatment as well as prophylaxis. But resistance is 
reported due to mutation in the Pneumocystis DHFR, DHPS gene which is the target 
for TMP-SMX and leads to treatment failure (21). High prevalence rate of DHPS gene 
mutation is reported in developed countries than in developing countries i.e 72% in 
USA, 56% in Africa, 6.2% in India (57). 
 
 
 
 
40 
 
4.  Materials and methods 
 
4.1. Study design: 
This was a prospective study of diagnostic test accuracy for a period of one year, 
conducted in the Department of Clinical Microbiology, Christian Medical College and 
Hospital, Vellore.  
In this study, respiratory samples were collected from adult immunocompromised 
patients with respiratory illness and PCP as one of the differential diagnosis. All 
samples were subjected to conventional microscopic methods such as Giemsa 
staining, direct fluorescent antibody test and the molecular diagnostic method - real 
time quantitative PCR assay.  
According to EORTC (European Organization for Research and Treatment of 
Cancer/Invasive Fungal Infections Cooperative Group) clinical criteria, patients were 
categorized into definite PCP, probable PCP and non PCP based on symptoms, signs, 
radiological features, and response to anti-pneumocystis treatment. Results of the 
molecular test was compared against the EORTC clinical criteria. 
4.2. Ethics approval: 
The approval for the study was obtained from the Institutional Review Board, CMC, 
Vellore (IRB Min No: 8824 [DIAGNOSE] dated 07.04.2014). 
4.3. Study duration: 
The study was conducted over a period of one year from June 2014 to May 2015. 
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4.4. Study samples: 
Respiratory samples like induced sputum, endotracheal aspirate (ETA), and Broncho 
alveolar lavage (BAL) sent for routine diagnosis of PCP by DFA test were taken for 
this study.  
 
The Department of Clinical Microbiology is an NABL Accredited laboratory. It has 
different sections handling different kinds of samples. More than 6 lakhs samples are 
processed per year. Mycology section receives more than 6000 samples a year, of 
which 150 to 200 samples per year are received are for Pneumocystis jirovecii DFA 
test. 
 
The Department of Infectious Diseases and Research Centre (IDRC) in CMC Vellore 
conducts HIV clinic thrice a week. They see more than 4000 patients in a year. 
Voluntary Counselling and Testing Centre (VCTC) which is part of their department  
does HIV testing and pre and post-test counselling to 1400 to 1500 patients  a year of 
which around 170 to 200 patients are found to be HIV  positive. 
 
The Department of Haematology in CMC, Vellore sees 1200 new out patients every 
year and admits about 700 patients every year for inpatient care. These patients come 
from all over India and cover the whole spectrum of blood diseases. They perform 110 
allogenic bone marrow transplantation per year. 
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4.5. Sample size calculation: 
Due to the paucity of data on the prevalence of PCP in India, sample size could not be 
calculated, and a pilot study was conducted. 
Thirty (30) HIV infected and seventy (70) non-HIV infected immunocompromised 
patients with suspected PCP were enrolled in this study as per the inclusion criteria. 
4.6. Inclusion criteria: 
i. Respiratory samples from adult immunocompromised patients with symptoms 
and signs suggestive of PCP. 
ii. Only one sample from each patient was included, if multiple samples were sent 
from the same patient. 
4.7. Exclusion criteria: 
i. Samples from non-immunocompromised patients were excluded. 
ii. Unsatisfactory samples such as samples with excessive salivary 
contamination were excluded. 
iii. Samples from paediatric patients who were less than 18 years were also 
excluded. 
4.8. Data source: 
Relevant clinical information like age, sex, admitted unit, HIV status, CD4 counts if 
HIV positive, cause for immunosuppression, cardinal symptoms like fever, dry cough, 
progressive dyspnoea, PaO2 value, radiological features, and treatment history were 
collected from patient’s clinical record. Testing of the study samples were done in the 
department of Clinical Microbiology. 
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4.9. Study algorithm:  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Respiratory samples from these patients sent for routine diagnosis of PCP 
were taken after getting informed consent 
100 Adult immunocompromised patients who had respiratory illness with 
PCP as one of the differential diagnosis 
Induced sputum (56), ETA (22), and BAL (22) were centrifuged at 3000 rpm 
for 20 minutes  
From the pellet, two smears 
were made for Giemsa 
staining and DFA 
Rest of the pellet was washed 
twice in phosphate buffer saline 
(PBS) and resuspended in 1ml of 
PBS, and stored at -70°C 
DNA extraction using QIAmp 
DNA mini kit 
Real time quantitative PCR 
Results were compared with 
clinical stratification of disease 
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4.10. Processing of study samples: 
A. Induced sputum: 
Purulent material from the induced sputum was taken into a test tube and equal 
amount of freshly prepared 1% dithiothreitol (DTT) was added and incubated at room 
temperature for 30 to 45 minutes with intermittent vortexing. Then centrifuged at 
3000rpm for 20 minutes. The supernatant was discarded and two smears were made 
from the deposit, one for Giemsa staining and one for DFA. 
B. BAL and ETA: 
BAL and ETA were centrifuged at 3000 rpm for 20 minutes and the supernatant was 
discarded. Two smears were made from the deposit, one for Giemsa staining and one 
for DFA. 
C. For real time quantitative PCR (qPCR): 
For qPCR assay, the pellet (deposit) was washed twice in phosphate buffer saline 
(PBS) and resuspended in 1ml of PBS. This was aliquoted into two separate vials and 
stored at -70°C. 
4.11. Giemsa staining procedure: 
i. Smear was fixed by methanol. 
ii. Slide was immersed into a Petri dish containing Giemsa stain for 30 minutes. 
iii. Then the slide was washed under slow running tap water. 
iv. The smear was screened under oil immersion objective. 
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4.12. Direct fluorescent antibody test procedure: 
i. Smear was fixed by acetone. 
ii. 50µl of detection reagent (MERIFLUOR) containing FITC labelled 
monoclonal antibodies against cell wall and matrix antigens of P. jirovecii 
cysts, sporozoites and trophozoites was added to sample well. 
iii. Slide was incubated at 37ºC in a moist chamber for 30 minutes.  
iv. Stain was removed by washing under slow running tap water.  
v. The slide was immersed in a Coplin jar containing tap water, and agitated in 
between for 7-10 minutes.  
vi. Mounting fluid was added to the smear and cover slip applied.  
vii. The slide was screened under fluorescence microscope at 20X and 40X 
magnification. 
 
4.13. Real time quantitative PCR assay: 
Principle:  
Polymerase chain reaction amplifies a specific target region of the template DNA 
strand. In real time quantitative PCR assay, PCR product is measured at each cycle in 
real time by fluorescent dyes that yield increasing fluorescent signal in direct 
proportion to the number of amplicons produced. 
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4.13.1. DNA extraction: 
A. Materials required: 
 QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) containing:  
                      Proteinase K  
                      Lysis buffer AL  
                      Wash buffer 1 AW1  
                      Wash buffer 2 AW2  
                       Elution buffer AE  
                       QIAamp Mini Spin Columns  
                       Collection Tubes (2 ml)  
 Ethanol  
 Nuclease free water  
 Dry bath (temperature to be set at 56°C) 
B. Procedure: 
DNA extraction was performed in the ‘PCR dirty’ room as per manufacturer’s 
instructions.  
i. 20μl Qiagen Proteinase K was taken in the bottom of a 1.5 ml micro 
centrifuge tube.  
ii. 200μl resuspended pellet was added to the micro centrifuge tube.  
iii. Then, 200μl Buffer AL (lysis buffer) was added to the sample in the 
same tube.  
iv. These substances were mixed well by pulse vortexing for 15 seconds.  
v. The tube was incubated at 56°C for 10 minutes.  
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vi. After this, the tube was briefly centrifuged to remove the drops from 
inside the lid.  
vii. 200μl of absolute alcohol was added to the tube. 
viii. Again, it was mixed well by pulse vortexing for 15 seconds.  
ix. Then, the tube was briefly centrifuged to remove the drops from inside 
the lid.  
x. The mixture was placed in the QIAamp spin column with a 2 ml 
collection tube without wetting the rim and the cap was closed.  
xi. The spin column was centrifuged at 8000 rpm for 1 minute.  
xii. The QIAamp spin column was placed in a clean 2 ml collection tube and 
the collection tube containing the filtrate was discarded.  
xiii. The QIAamp spin column was carefully opened and 500μl Buffer AW1 
(Wash buffer) was added to it without wetting the rim and the cap was 
closed.  
xiv. It was centrifuged at 8000 rpm for 1 minute.  
xv. The QIAamp spin column was placed in a clean 2 ml collection tube and 
the collection tube containing the filtrate was discarded.  
xvi. The QIAamp spin column was carefully opened and 500μl Buffer AW2 
(Wash buffer) was added without wetting the rim and the cap was 
closed. 
xvii. It was centrifuged at full speed of 14,000 rpm for 3 minutes.  
xviii. The QIAamp spin column was placed in a clean 1.5 ml microcentrifuge 
tube and the collection tube containing the filtrate was discarded.  
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xix. The QIAamp spin column was carefully opened and 100μl Buffer AE 
(eluting buffer) was added to it.  
xx. The tube was incubated at room temperature for 1 minute. 
xxi. It was then centrifuged at 8000 rpm for 1 minute and the spin column 
was discarded.  
xxii. The 1.5 ml centrifuge tube contained DNA which was labelled and 
stored at -70°C in four aliquots. 
 
4.13.2. Quantification of Pneumocystis: 
Plasmids used for quantification were produced by cloning the PCR amplified product 
into the PCR-TOPO TA vector (TOPO® TA Cloning® kit, Invitrogen, Carlsbad, CA, 
USA). Nano drop method used for quantification of plasmids. Standard curve was 
generated by the amplification of a tenfold dilution series of a plasmid standard 
(2×109 to 2 ×105 copies/reaction).  Quantification was performed using ABI (Applied 
Bio system) 7500 Fast PCR system software by extrapolation of data to standard 
curves.  
 
4.13.2.1. Cloning: 
Cloning was done with TOPO TA Cloning® Kit (with pCR®2.1-TOPO® and 
PureLink™ Quick Plasmid Miniprep Kit) 
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Principle: 
Taq polymerase used in PCR has a nontemplate-dependent terminal transferase activity 
that adds a single deoxyadenosine (A) to the 3´ ends of PCR products. The linearized 
vector supplied in TOPO TA Cloning® kit has single, overhanging 3´ deoxythymidine 
(T) residues. This allows PCR inserts to ligate efficiently with the vector.  
 
                                                               
Primers for cloning: 
Primers for cloning were designed by online Primer 3 software (Version 0.4.0). These 
primers amplifies 700-bP fragment of Pneumocystis jirovecii mitochondrial large 
subunit rRNA (mtLSU rRNA) gene which contained the segment (120-bp) used for 
qPCR assay. 
The lyophilised primers used for the cloning were reconstituted in 1X Tris EDTA (TE) 
buffer and stored as single use aliquots at -20°C. The primer sequences were as follows: 
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Primers Sequence 
PjcF 5’-TCGGCGAATAGGATTTTCAC-3’ 
PjcR 5’-TTGCATAATGGGTCAGCAAG-3’ 
 
Cloning procedure: 
A. Production of PCR products: 
This was done with two known DFA positive samples. 
The concentrations of the different components of the PCR mix for one reaction are 
given below: 
 
Reagents 
 
For one reaction 
Hot start mix 12.5µl 
PjcF primer 0.5 µl (20µM concentration) 
PjcR primer 0.5 µl (20µM concentration) 
Water 9.0 µl 
Extracted DNA 2.5 µl 
Total volume 25 µl 
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A conventional PCR method was carried out in Gene-AMP PCR system 9700 (Applied 
Biosystem). 
The cycling conditions were as follows; 
           Initial holding at 95°C for 15 minutes 
           Denaturation at 94°C for 30 seconds 
           Annealing at 52°C for 30 seconds             - 35 cycles 
           Extension at 72°C for 1 minute 
           Final extension at 72°C for 1 minute 
Amplicons were checked by 2% agarose gel electrophoresis and it showed a single 
discrete band at 700bp. 
 
 
 
700bp
pp 
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B. Per formation of TOPO Cloning reaction:  
TOPO cloning reaction was set up with following reaction mix: 
 
Reagent  Volume 
Fresh PCR product 4 µl 
Salt solution 1 µl 
TOPO vector 1 µl 
Final volume 6 µl 
 
Reaction was gently mixed and incubated at room temperature for 5 minutes. 
 
C. Transformation of one shot competent cells: 
Requirements for transformation: 
LB (Luria-Bertani) plates containing 50 μg/mL ampicillin  
S.O.C. medium (supplied with the kit) 
40 mg/ml X-gal in dimethylformamide (DMF) 
42°C water bath  
37°C shaking and non-shaking incubator  
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LB medium preparation: 
Ingredients: 
Agar                     - 1.5g 
Tryptone               - 1.0g 
Yeast extract        - 5.0g 
Sodium chloride   - 1.0g 
De-ionized water   - 95ml 
pH                          - 7 (adjusted by using 1N NaOH) 
Ingredients were mixed well by heating, autoclaved and cooled to 55°C. To this 
ampicillin 50 µg/ml was added.  
100 ml of LB broth was prepared without agar. 
Transformation Procedure: 
i. 2µl TOPO cloning reaction was added into a vial of one shot chemically 
competent E.coli and mixed gently (not by pipetting up and down). 
ii. Reaction was incubated on ice for about 30 minutes. 
iii. The cells were heat shocked for 30 seconds at 42°C without shaking. 
iv. The tube was transferred immediately to ice. 
v. 250 µl of S.O.C medium was added (The medium was brought to room 
temperature before the procedure) 
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vi. The tube was capped tightly and kept in the shaker at 200 rpm speed in 37°C 
incubator for 1 hour. 
vii. 40 µl of X-gal was overlayed on LB plate (containing 50µg/ml ampicillin) to 
differentiate transformed (white colonies) from non-transformed, self-ligated 
plasmid colonies (Blue colour). 
viii. 50 µl of transformation was spread on prewarmed (37°C) LB agar. 
ix. LB agar plate was incubated at 37°C for 24 hours. 
 
D. Analysis of transformants: 
Approximately two to four white colonies were taken from the plate and inoculated into 
LB broth containing ampicillin 50 µg/ml and incubated at 37°C overnight. Extraction of 
plasmid was carried out from the LB broth using PureLink Quick Plasmid DNA Mini 
Prep Kit (given along with TOPO TA Cloning® Kit). 
Plasmid extraction: 
The PureLink Quick Plasmid DNA Mini Prep Kit was designed to isolate high quality 
plasmid DNA up to 30 µg from E.coli cells in 30 to 45 minutes. 
Principle: 
Cells are lysed by alkaline substances and the lysate applied to silica membrane column 
that selectively binds plasmid DNA. Contaminants are removed by wash buffers and 
plasmid DNA is eluted in TE buffer. 
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The PureLink Quick Plasmid DNA Mini Prep Kit  containing 
             Resuspension buffer 
             RNase A 
             Lysis buffer 
             Precipitation buffer 
            Wash buffer W9 and W10 
            TE buffer 
            Wash and recovery tubes 
             Spin column 
Procedure: 
i. 5 ml of overnight LB broth was centrifuged to sediment the cells  
ii. 250 µl of resuspension buffer with RNase A was added to the cell pellet and the 
pellet was resuspended until it was homogeneous 
iii. To it 250 µl of lysis buffer was added and mixed gently by inverting the capped 
tube five times. This was incubated at room temperature for 5 minutes. 
iv. 350 µl of precipitation buffer was added and mixed immediately by inverting the 
tube until the mixture was homogeneous. The lysate was centrifuged at 14000 
rpm for 10 minutes 
v. Supernatant from the tube was added to the spin column in a 2 ml wash tube and 
the column was centrifuged at 14000 rpm for 1 minute 
vi. 500 µl of wash buffer (W10) was added to the column and incubated at room 
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temperature for 1 minute, then the column was centrifuged at 14000 rpm for 1 
minute. Flow through was discarded and the spin column was placed in a new 
wash tube 
vii. 700 µl of wash buffer (W9) was added and the column was centrifuged at 14000 
rpm for 1 minute. Flow through was discarded and the spin column was placed 
in a new wash tube. The column was centrifuged at 14000 rpm for 1 minute. 
Wash tube with flow through was discarded. 
viii. Spin column was placed in a clean 1.5ml recovery tube. 75 µl of TE buffer was 
added to the centre of the column and incubated at room temperature for 1 
minute. 
ix. The spin column was centrifuged at 14000 rpm for 2 minutes and the column 
was discarded. The recovery tube, which contained purified plasmid DNA, was 
aliquoted and stored at -20°C 
 
E. Analysis of plasmid: 
Extracted plasmid DNA was analysed by two methods.  
i. The first method was by conventional PCR using cloning primers, with same 
reaction mix formula and cycling condition as described above. The PCR 
product was analysed by 2% agarose gel electrophoresis and there was a discrete 
band at 700 bp. 
ii. The second method was another conventional PCR using M13 Primers provided 
with the kit for sequencing. 
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The primer sequences were as follows: 
Primer  Sequences 
M13 Forward 5’-GTAAAACGACGGCCAG-3’ 
M13 Reverse 5’-CAGGAAACAGCTATGAC-3’ 
 
The concentrations of the different components of the PCR mix for one reaction are 
given below: 
Reagents For one reaction 
Hot start mix 25 µl 
M13 Forward primer  1 µl 
M13 Reverse primer  1 µl 
Water 18 µl 
1/10 diluted plasmid DNA  5 µl 
Total volume 50 µl 
 
The cycling conditions were as described above for cloning and the PCR product was 
analysed by 2% gel electrophoresis. There was a discrete band at 900bp. 
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F. Quantification of plasmid DNA: 
Quantification of plasmid DNA was done by Nano drop method. 
Undiluted plasmid was containing 114.3 ng/µl of DNA. 
Copy numbers were calculated by “URI genomics & sequencing centre calculator for 
determining the number of copies of a template” from “cels.ur.edu/gsc/cndna.html” 
website. 
The formula used is: 
number of copies = ( amount * 6.022x1023) / (length * 1x109 * 650) 
Copy numbers in the undiluted plasmid was found to be 2.29 × 1010 copies. 
 
 
900bp 
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4.13.3. Standardization of real time quantitative PCR assay: 
The assay was standardised by running PCR assay several times with different 
concentration of probe i.e. 0.2 µM, 0.1 µM and different temperature annealing and 
extension such as 50°C, 52°C, 54°C, 56°C and 60°C. We got a good sigmoidal curve at 
54°C with 5 µM concentration of probe. So we finalised that temperature and 
concentration. 
4.13.4. Real time quantitative PCR assay procedure for Pneumocystis jirovecii: 
Primers for qPCR: 
The lyophilised primers and probes used for the qPCR were reconstituted in 1X Tris 
EDTA (TE) buffer and stored as single use aliquots at -20°C. The primer and probe 
sequences were as follows: 
Primers Sequence 
PjF1 5′-CTGTTTCCCTTTCGACTATCTACCTT-3′ 
PjR1 5′-CACTGAATATCTCGAGGGAGTATGAA-3′ 
PjP1 5′- FAM-TCGCACATAGTCTGATTAT-
NFQMGB-3′ 
 
The primers target 121-bp fragment of P.jirovecii mitochondrial large subunit rRNA 
(mtLSUrRNA) gene (13). 
Master Mix preparation: 
The concentrations of the different components of the PCR mix for one reaction are 
given below: 
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Reagents For one reaction 
TaqMan Universal Master mix  (Applied 
Biosystems) 
12.5 µl 
PjF1 1.0 µl (0.4µM concentration) 
PjR1 1.0 µl (0.4µM concentration) 
TaqMan-MGB probe PjSL 0.5 µl (0.2µM concentration) 
Extracted DNA 10 µl 
Total volume of reaction 25 µl 
 
Procedure for amplification: 
i. The master mix was prepared in the clean room or ‘DNA-free’ room for 
the appropriate number of reactions with the above template.  
ii. A 96 well PCR reaction plate was taken, 15 µl master mix was added to 
each well. 
iii. DNA extracts were removed from the storage area, brought to room 
temperature.  
iv. 10 μl of DNA was added to the well according to the template made and 
the final volume was 25 μl. Addition of DNA was done in the ‘dirty 
room’.  
v. Nuclease free water was used as negative control after every three 
samples.  
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vi. In each cycle five standards (1×108 to 104) and one positive control were 
used. 
vii. Amplification reactions were carried out in ABI 7500 Fast PCR system. 
viii. The cycling conditions were: 
                        Initial holding temperature at 95⁰C for 10 minutes. 
             Denaturation at 95⁰C for 15 seconds 
            Annealing and extension at 54⁰C for 1 minute 
            Total number of cycles are 45. 
PCR analysis: 
PCR analysis was done with ABI 7500 Fast PCR system software. 
Determination of the limit of detection of Pneumocystis jirovecii qPCR:  
The lower limit of detection of the assay was determined by testing of serial dilutions 
of the plasmid standards which used for quantitation. The undiluted plasmid standard 
contained 2 × 1010 copies/ml. The standards were serially diluted so as to obtain  
1× 10-1 to 1 × 10-10 dilutions of undiluted plasmid. The copies number in the 
corresponding dilutions were 2 × 109   to 2 copies/ml.  The dilutions were then tested in 
triplicates. Copies number in the lowest dilutions which were detected by qPCR assay 
was determined as limit of detection of the assay. The lower limit of detection of the 
assay was determined to be 20 to 200 copies/ml. 
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 Specificity of the qPCR: 
The specificity of qPCR assay was tested with three sputum samples which were high 
positive for Mycobacterium tuberculosis, Candida albicans, and Streptococcus 
pneumoniae (heavy growth in culture). 
4.13.5. Internal control: 
In order to search for integrity of DNA as well as PCR inhibitors, each clinical sample 
was tested in a second reaction mixture containing primers and probes for Human 
RNase P gene (designed at CDC). Human RNase P gene is a single-copy gene 
encoding the RNA moiety for the RNase P enzyme.  
The primer and probe sequences were as follows; 
Primers Sequences 
Forward (HURNASE-P-F) 5’-AGA TTT GGA CCT GCG AGC G -3’ 
Reverse (HURNASE-P-R) 5’-GAG CGG CTG TCT CCA CAA GT- 3’ 
Probe (BHQ1HURNASE-P) 5’FAM-TTC TGA CCT GAA GGC TCT GCG CGBHQ-
3’ 
 
 
The concentration of different components of the PCR mix for one reaction are given 
below: 
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 Reagents                                                   For one reaction 
TaqMan Master Mix (Invitrogen) 12.5 µl 
PCR water   2.45 µl 
MgCl2  1.5 µl 
Forward primer  2.0 µl 
Reverse primer  2.0 µl 
Probe  2.0 µl 
Rox  0.05 µl 
DNA extract  2.5 µl 
Total volume 25 µl 
 
PCR was carried in Applied Bio Systems 7500 Fast Real time PCR system.  
The cycling conditions were as follows; 
                  Initial holding temperature at 95°C for 10 minutes 
                  Denaturation at 95°C for 15 seconds            
                 Annealing and extension at 65°C for 1 minute 
                 Total number of cycles are 50 
PCR analysis: 
CT (cycle threshold) value below 35 was taken as satisfactory.  
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4.14. Categorization of patients: 
Recruited patients were categorized into definite PCP, probable PCP, and non PCP 
based on following criteria (11): 
Definite PCP 
 Patients presented with typical symptoms of PCP such as fever, dry cough, 
and progressive dyspnea 
 Bilateral interstitial infiltration on chest X-ray or ground glass opacity on 
high resolution CT thorax. 
 Clinical response to anti-pneumocystis treatment and 
 DFA test positive in respiratory samples.  
Probable PCP  
 Patients presented with typical symptoms of PCP and meet all the criteria 
for “definite PCP” except that DFA give negative results. 
Non-PCP 
 Patients who presented with atypical symptoms 
 Variant lung infiltrations on chest X-ray 
 Clinical response to other antimicrobial agents  
 Have other definite diagnosis. 
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4.15. Statistical methods: 
All the patient parameters and test results were entered in EpiData. The distribution of 
age among the categories was analysed using one way ANOVA. This has been 
presented with mean and standard deviation. Categorical variables were presented 
with frequency and percentage while their association with the diagnosis was assessed 
using chi-square test or fisher’s exact test. AUC (Area under Receiver Operating 
Characteristic (ROC) curve) was given for the copy numbers comparing with DFA. 
For all the analyses done using statistical software STATA 13.1, p-value of less than 
0.05 was considered as statistically significant.  
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5. Results: 
 
5.1. Demographic data: 
During the period of study from June 2014 to May 2015, 189 samples were received 
for routine DFA test, in which five samples were positive by DFA. 
After considering the inclusion and exclusion criteria as mentioned in materials and 
methods section, 100 respiratory samples were included in the study. 
All the samples included in the study were from adult immunocompromised patients 
only. 
Fig. 5.1 shows the patient distribution. 
30 (30%) samples were from HIV infected patients and 70 (70%) samples i.e. two 
third were from non-HIV infected immunocompromised patients. 
 
 
 
30%
70%
Fig.5.1 Patient distribution
HIV
Non-HIV
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Fig. 5.2 shows the percentage distribution of non-HIV immunocompromised patients. 
Among the seventy non-HIV infected immunosuppressed patients, 27 (38.6%) had 
haematological malignancies, 29 patients (41.4%) were on immune suppressive 
therapy for auto immune disorders, eight had (11.4%) solid organ malignancies and 
six patients (8.6%) were post renal transplantation. 
 
 
 
Fig. 5.3 shows the patient distribution in haematological malignancies. In this group 
(n=27), patients had different diseases like multiple myeloma (n=7), lymphoma (n=7), 
myelodysplastic syndrome (n=3), auto immune lympho proliferative syndrome (n=3), 
chronic lymphoid leukaemia (CLL) (n=3), acute myeloid leukaemia (AML) (n=2), 
acute lymphoid leukaemia (ALL) (n=1), and chronic myeloid leukaemia (CML) 
(n=1).  
Haematological 
malignancies, 38.60%
Auton immune 
disorders, 41.40%
Solid organ 
malignancies, 11.40%
Renal transplantation, 
8.60%
Fig. 5.2 Distribution of non-HIV infected patients
Haematological malignancies Auton immune disorders
Solid organ malignancies Renal transplantation
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Fig. 5.4 shows the distribution of patients in auto immune disorders. 
Following were the disorders found in this group of patients (n=29) i.e interstitial lung 
disease (ILD) (n=6), dermatomyositis (n=5), Wegener’s granulomatosis (n=5), 
inflammatory myopathy (n=3), systemic lupus erythematosus (SLE) (n=3), auto 
immune glomerulo nephritis (n=2), and systemic sclerosis, diffuse scleroderma, hyper 
eosinophilic syndrome (HES), undifferentiated auto immune disorder were found in 
single patient. 
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Fig. 5.3 Patient distribution in haematological malignancies
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Fig. 5.5 Shows percentage distribution of the patients from various departments  
Majority of samples i.e 41% were from medicine units, followed by 27% from 
haematology, 19% from pulmonary medicine and rest from nephrology (8%) and 
rheumatology units (5%). 
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Fig 5.4 Patient distribution in auto immune disorders
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Fig. 5.6 Shows sex distribution. 
Sixty three (63%) samples were from males and 37 (37%) were from females. The sex 
distribution was found to be slightly on the higher side for males. 
 
Fig. 5.7 shows the sample distribution. 
Fifty six (56%) samples were induced sputum, rest were 22 each of Brochoalveolar 
Lavage (BAL) and Endotracheal aspirate (ETA) (22% each). Two third of the samples 
were non-invasive samples like induced sputum and ETA. 
 
Male, 63%
Female, 37%
FIG. 5.6 SEX DISTRIBUTION
56%
22%
22%
Fig. 5.7 Sample distribution
Induced sputum ETA BAL
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5.2. Patient categorization: 
Fig. 5.8 shows the percentage distribution of different categories of PCP. 
The patients who were recruited for this study have been categorized based on the 
criteria as mentioned in material and methods section. Five patients (5%) were 
categorized into definite PCP, 20 patients (20%) into probable PCP, and 75 patients 
(75%) into non-PCP groups. 
 
 
 
Fig. 5.9 shows final diagnosis in non-PCP group. 
The final diagnosis in non-PCP patients (n=75) were tuberculosis (TB) (n=10), 
atypical pneumonia (n=9), superadded infection of ILD (n=9), pleural effusion (n=6), 
acute respiratory distress syndrome (n=6), nocardiosis (n=4), fugal pneumonia (n=3), 
H1N1 pneumonia (n=3), Cytomegalo virus (CMV) pneumonia (n=3), febrile 
Definite PCP, 5%
Probable PCP, 20%
Non-PCP, 75%
Fig. 5.8 Patient categorization
Definite PCP Probable PCP Non-PCP
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neutropenia (n=3), bacterial pneumonia (n=2), pneumothorax (n=2), emphysema 
(n=1), and mediastinal lymphadenopathy (n=1). Thirteen patients who do not have 
any diagnosis were categorised as undetermined. 
 
 
5.3. Patient demographics and clinical characteristics: 
Table. 5.1 depicts different clinical characteristics of the study patients. 
The age of the patients ranged from 20 years to 69 years. When observed for the age 
distribution, mean age for all three groups were almost same (40 and 43).  
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Fig. 5.9 Final diagnosis in non-PCP
Diagnosis in non-PCP
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In Definite PCP group, HIV infection was found in two patients (40%), 
haematological malignancy in one (20%), and two patients (40%) on 
immunosuppressive therapy for auto immune disorders. 
 
In Probable PCP group, nine patients (45%) were HIV infected, five (25%) had 
haematological malignancies, four patients (40%) were on immunosuppressive 
therapy for auto immune disorders, and two (20%) were post solid organ 
transplantation. 
 
In Non-PCP group, 19 patients (25%) were HIV infected, 21 (28%) had 
haematological malignancies, eight (11%) had solid organ malignancies, 23 patients 
(31%) were on immunosuppressive therapy for auto immune disorders, and four (5%) 
were post solid organ transplantation. 
 
Among the cardinal symptoms of PCP, fever was present in 80% of definite and 
probable group. Dry cough was found in 60% of definite and 75% of probable group. 
Progressive dyspnoea was seen in all (100%) definite and 95% of patients in probable 
group.  
Radiological features suggestive of PCP were found in all (100%) patients of both 
definite and probable group. 
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Dry cough and radiological features were found to be statistically significant with p 
values 0.001 and 0.00 respectively. 
CD4 counts were available for 27 patients. Median count in definite, probable and 
non-PCP group were 53, 37.5, and 70 respectively. Except five patients in non-PCP 
group others had CD4 counts less than 200/mm3 and this found to be statistically 
insignificant. 
 
Table. 5.1 Clinical and radiological characteristics of the study patients: 
Characteristics Definite PCP 
(n = 5) 
Probable PCP 
(n = 20) 
Non-PCP 
(n = 75) 
p value 
Age years (mean) 40 43 43 0.9086 
Sex (Male/female) 2/3 15/5 46/29 0.292 
Underlying conditions    0.586 
i. HIV infection 
(n = 30) 
2 (40%) 9 (45%) 19 
(25.33%) 
 
ii. Haematological 
malignancies  
(n = 27) 
1 (20%) 5 (25%) 21 (28%)  
iii. Solid organ 
malignancies 
(n = 8) 
0 0 8 (10.67%)  
iv. Auto immune 2 (40%) 4 (20%) 23  
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disorders on 
immune 
suppressive therapy 
(n = 29) 
(30.67%) 
v. Solid organ 
transplantation  
(n = 6) 
0 2 (10%) 4 (5.33%)  
Fever  4 (80%) 16 (80%) 50 
(66.67%) 
0.452 
Dry cough 3 (60%) 15 (75%) 23 
(30.67%) 
0.001 
Dyspnoea 5 (100%) 19 (95%) 57 (76%) 0.085 
Radiological features 
suggestive of PCP 
5 (100%) 20(100%) 8 (10.67%) 0.000 
CD4 counts/mm3 (median) 
(n=27) 
Number of patients with 
       < 200/mm3 
        > 200/mm3 
53 
 
 
1 
0 
37.5 (6-176) 
 
 
8 
0 
70 (4-883) 
 
 
13 
5 
0.2871 
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5.4. The test results: 
5.4.1 Giemsa staining: 
All the samples were subjected to Giemsa staining technique, which is one of the 
stains used to demonstrate trophic forms of Pneumocystis jirovecii. Here the nuclei 
stain reddish purple and cytoplasm light blue. None of the study samples were positive 
by Giemsa staining. All the smears were screened by a skilled microbiologist 
5.4.2 Direct immunofluorescent antibody (DFA) test: 
DFA was performed on all the samples. This method identifies both trophozoite and 
cyst forms of Pneumocystis jirovecii, where a characteristic honeycomb appearance is 
seen.  
Table. 5.2 shows results of DFA which was positive in five patients in the definite 
PCP group and negative in rest of the patients.  
Table. 5.2 DFA results 
DFA test Definite PCP 
(n=5) 
Probable PCP 
(n=20) 
Non-PCP  
(n=75) 
Positive 5 (100%) 0 (0%) 0 
Negative 0 20  75 (100%) 
Total 5 20 75 
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5.4.3 Real time quantitative PCR (qPCR) assay: 
Real time quantitative PCR assay was done on all the samples and positive results 
were given in copies/ml.  
Table. 5.3 shows qPCR results, which was positive in three samples from the definite 
PCP group, four from the probable PCP group and one from the non-PCP group. Two 
samples positive by DFA test were negative by qPCR. 
 
Table. 5.3 qPCR assay results: 
qPCR assay Definite PCP 
(n=5) 
Probable PCP 
(n=20) 
Non-PCP  
(n=75) 
Positive 3 (60%) 4* (20%) 1 (1.33%) 
Negative 2 (40%) 16 (80%) 74 (98.67%) 
Total 5 20 75 
* Two patients were diagnosed clinically as definite PCP   
 
Specificity of qPCR: 
Specificity of qPCR was tested with Mycobacterium tuberculosis, Candida albicans, 
and Streptococcus pneumoniae positive samples. All three samples were negative and 
no cross reactivity was found.  
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              Fig. 5.10. Representative amplification plot of qPCR 
 
                                 
                      Fig. 5.11. Representative Standard curve for qPCR 
S 1 
S 2 
S 3 
S 4 
S 5 
 Sample 
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Internal control: 
Human RNase P gene was tested in all the study samples to look for integrity of DNA 
and PCR inhibitors. All samples were found to be satisfactory and PCR inhibitors 
were ruled out. 
5.4.4 Comparison of qPCR assay and DFA test: 
Table. 5.4 Shows the comparative results of qPCR and DFA test. 
The comparison between these two tests showed that, DFA was able to detect 
Pneumocystis jirovecii when the copy numbers were more than 4540/ml. However, 
DFA failed to detect one of the samples which had 6990 copies/ml in qPCR 
 
Table. 5.4 Comparison of qPCR and DFA test results: 
qPCR 
positive 
patients 
Copies/ml Type of 
immunosuppression 
Assigned  
category 
DFA result 
Patient 1 530 Non-HIV Non PCP Negative 
Patient 2 1660 HIV Probable PCP Negative 
Patient 3* 1700 HIV Probable PCP Negative 
Patient 4 3640 HIV Probable PCP Negative 
Patient 5* 6990 HIV Probable PCP Negative 
Patient 6 4540 Non-HIV Definite PCP Positive 
Patient 7 23670 HIV Definite PCP Positive 
Patient 8 60850 Non-HIV Definite PCP Positive 
* These patients were diagnosed clinically as definite PCP. 
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5.4.5 Sensitivity and specificity of each test: 
Table. 5.5 Shows sensitivity, and specificity of DFA and qPCR tests. Here we have 
combined definite and probable PCP into a single group (diseased) and non-PCP as a 
separate group. It was found that qPCR assay had higher sensitivity (28%) than DFA 
test (20%), but statistically insignificant (p = 0.257). 
Table. 5.5 Sensitivity and specificity of DFA and qPCR 
Test Sensitivity Specificity 
DFA test 20% 100% 
qPCR assay 28% 98.67% 
 
9.4.6 Receiver Operating Characteristic curve (ROC) analysis: 
In a ROC curve the true positive rate (Sensitivity) of qPCR was plotted in function of 
the false positive rate (100-Specificity) for different cut-off points. Each point on the 
ROC curve represents a sensitivity/specificity pair corresponding to a particular 
decision threshold. The area under the ROC curve (AUC) is a measure of how well a 
parameter can distinguish between two diagnostic groups (diseased/normal). 
 
ROC curve analysis produced an AUC (Area under the ROC curve) of 0.78, along 
with a sensitivity (60%) and a specificity of 98.95% with a cut off value of 4540 
copies/ml (Fig. 5.12). 
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 Fig. 5.12 ROC curve 
Table. 5.6 Detailed report of sensitivity and specificity: 
Copies number/ml Sensitivity Specificity Correctly classified 
≥ 0 100% 0% 5% 
≥ 530 60%         94.74%        93%       
≥ 1660 60%         95.79%        94%       
≥ 1700 60%         96.84%        95%       
≥ 3640 60%         97.89%        96% 
≥ 4540 60%         98.95%        97%       
≥ 6990 40%         98.95%        96% 
≥ 23670 40%        100%        97% 
≥ 60850 20%        100%        96%                     
˃ 60850 0%        100%        95%                     
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5.5. Cost effectiveness analysis: 
Cost effectiveness analysis for DFA and qPCR assay were done with the help of 
Accounts department from our institution, under following categories (Table 5.7) for 
a batch of five tests per week. Found to be qPCR assay is cheaper than DFA test. 
 
Table. 5.7 Cost accounting details for DFA and qPCR 
 DFA (Rs) qPCR (Rs) 
Personnel 1320 1320 
Equipment 400 490 
Consumables 950 1050 
Chemicals and reagents 13000 7520 
General 2130 2235 
Total 17800 12615 
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6. Discussion: 
 
Pneumocystis jirovecii is an important opportunistic pathogen causing pneumocystis 
pneumonia (PCP) in immunosuppressed individuals. With the introduction of highly 
active anti retro viral therapy (HAART) and anti-Pneumocystis prophylaxis, the 
incidence of PCP has declined in HIV infected individuals. However, this has become 
an emerging pathogen in non-HIV infected immunosuppressed patients and accounts 
for high mortality rate. PCP in this group of patients presents with an abrupt onset of 
symptoms and progresses rapidly to respiratory failure and death if untreated. Thus, 
laboratory diagnosis plays an important role in management of PCP. The diagnostic 
tests for PCP should be rapid as well as reliable. 
In developing countries like India, the majority of PCP cases are diagnosed clinically. 
Since these organisms are non-cultivable, laboratory diagnosis is done by microscopic 
methods using Geimsa / Toludine blue O (TBO)/ Gomori methenamine silver (GMS) 
stains or by immunofluorescence methods. The major drawbacks of microscopy are 
the need for a skilled microbiologist and low sensitivity of the method (16). 
Currently, the molecular diagnostic methods are preferred as they are rapid and 
accurate with higher sensitivity. 
Polymerase chain reaction (PCR) is an important diagnostic technique for diagnosis 
of PCP as they are non-cultivable and low sensitivity of available microscopic 
methods. Real time quantitative PCR (qPCR) has the advantage of quantification of 
the pathogen over other conventional and nested PCR techniques. This discriminates 
active infection from colonization. 
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In CMC, Vellore PCP is diagnosed by microscopic methods using direct 
immunofluorescent antibody test (DFA) and Giemsa staining.  
In this study, qPCR assay targeting mitochondrial large subunit rRNA (mtLSUrRNA) 
gene of P.jirovecii was performed on 100 respiratory samples from HIV and non-HIV 
infected immunocompromised patients to evaluate this assay. 
 
6.1 Patient’s demography and clinical characteristics  
In our study, 70 out of 100 (70%) patients were non-HIV infected immunosuppressed 
individuals, which is similar to the study done by Alanio A et al. and Gupta R et al. In 
their study 169/ 238 (71%) and 170/275 (62%) patients were non-HIV 
immunocompromised (1,13).This indicates that PCP is on the rise in this group of 
patients. 
Presence of dry cough and radiological features suggestive of PCP such as bilateral 
reticular infiltration on chest X-ray or ground glass opacity in HRCT were the two 
features significantly associated with PCP in our study (p < 0.05). CD4 counts in 
definite and probable PCP were less than 200/mm3, were not significant (p= 0.287), as 
both non PCP and PCP patients had counts less than 200/mm3. This was in contrast to 
the findings by Chawla et.al who found significant association with low CD4 counts 
(16). 
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6.2 Use of Giemsa staining 
This study we found that Giemsa staining was not a useful technique for the diagnosis 
of PCP as none of the study samples were positive by this method. Positivity on light 
microscopy needs more than 105 organisms / ml in the clinical samples. The low 
copies of PCP in our samples might be the reason why we had no positives on smear 
microscopy using Giemsa stain. However, some studies showed higher levels of 
sensitivity in contrast to our experience. Chumpitazi et al. found that Giemsa staining 
had a sensitivity of 50% (9). Flori et al. and Jarboui et al. combined two staining 
methods such as Giemsa/GMS and Giemsa/TBO respectively. They found sensitivity 
of 60%, 64.3% and specificity of 100% (compared with the clinical diagnosis) 
(41,58). An Indian study by Chawla et al reported 43.7% (7/16) sensitivity for 
Giemsa/GMS methods (16).  
6.3 Use of DFA ours vs other studies  
In our study we found five out of 25 patients in the definite and probable group were 
positive by DFA. As we have included DFA positivity as one of the criteria for 
definite PCP, it is 100% positive in this group, though overall sensitivity was only 
20%. Hauser et al reported a higher sensitivity of 93% using Merifluor kit and Jarboui 
et al reported 78.5% when compared with clinical diagnosis (58,59). The reason for 
low sensitivity in our study may be due to larger number of patients we had in 
Probable PCP group than in Definite PCP group. Jarboui et al had only one patient 
out of 14 definite cases and Hauser et al had no patients in the probable PCP group. 
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6.4 Use of Molecular methods 
In our study, qPCR was positive in 60% (3/5) of definite PCP, 20% (4/20) of probable 
and 1.3% (1/75) of non-PCP patients. Overall sensitivity was found to be 28% in 
clinically suspected patients (Definite + Probable PCP) which is slightly higher than 
DFA. Several studies reported molecular method of any kind (qPCR, nested PCR, 
conventional PCR) had higher sensitivity over DFA (11,13,43,44,58,60).  
 
Alanio et al developed the qPCR assay targeting mtLSU rRNA gene and the results 
were compared with clinical classification of high and low probable PCP. The study 
described two cut-off values such as 120 and 1900 TFEq/ml (Trophic equivalent/ml) 
to discriminate active infection from colonization in low and high probable cases 
respectively. Sensitivity and specificity for the diagnosis of PCP were estimated as 
100% and 96.9% respectively with the lower cut-off value (120 TFEq/ml) (13). 
 
The primers and probes described by Alanio et al were used in our study. Highest 
sensitivity and specificity of 60% and 98.95% were obtained with the cut-off value of 
4540 copies/ml. ROC curve was made by true positivity of qPCR compared with 
DFA results. This huge difference of sensitivity between our study and Alanio et al 
could be due to difference in clinical criteria used in both studies. In their study 
patients were categorized into high probable (16/238) and low probable (222/238) 
cases based on clinical and radiological presentation. In our study we used the 
European Organization for Research and Treatment of Cancer/Invasive Fungal 
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Infections Cooperative Group (EORTC) Criteria and categorised patients in definite 
group if patients had typical symptoms like fever, dry cough, progressive dyspnoea 
with radiological features suggestive of PCP and shown clinical response to anti-
pneumocystis treatment, as well as positive DFA result. Patients who had all criteria 
of definite PCP except gave negative DFA result were categorised in Probable group. 
Non PCP were assigned to those who had atypical symptoms, variant lung 
infiltrations and other definite diagnosis.   
 
Alvarez-Martinez MJ et al compared qPCR and nested PCR targeting DHPS gene in 
microscopy-positive stored samples. The study found that sensitivity (94%) was same 
for both, but specificity of qPCR (96%) was significantly higher than nested PCR 
(81%) (61). 
 
Huggett JF et al described a qPCR method targeting HSP 70 (Heat shock protein) 
gene and compared with a conventional PCR targeting mtLSUrRNA gene of 
P.jirovecii and microscopy as gold standard. Estimated sensitivity, specificity for 
qPCR and conventional PCR were 98%, 96% and 97%, 68% respectively (42). Our 
study also showed the sensitivity and specificity of 60% and 94.74%, if qPCR was 
compared with DFA test. 
Direct comparison with other studies were difficult, as there are marked difference in 
target chosen, type of samples, group of patients studied and Gold standard test used 
to compare results (59,62).  
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6.4.1 DFA positive qPCR negative results: 
       In our study, we observed that two out of five samples were negative by qPCR, 
but positive by DFA. 
       One of the discrepant samples was collected from a newly diagnosed HIV 
positive treatment naive patient. The patient presented with fever for two months, 
cough with minimal mucoid expectoration and breathlessness for a month. A clinical 
diagnosis of PCP was made and the patient started on curative dose of co-trimoxazole 
five days before the collection of sample. This could be a false negative result and 
may be due to empty cyst without DNA after treatment as suggested by Caliendo et al. 
(63). 
         The second discrepant sample was obtained from a patient with chronic myeloid 
leukaemia in blast transformation phase. This patient presented with acute onset of 
fever, dry cough and worsening dyspnoea. Treatment for PCP with therapeutic dose of 
co-trimoxazole and steroid was started as induced sputum was positive by DFA test. 
However, the patient did not improve and needed mechanical ventilation for 
respiratory failure. Endotracheal aspirate had grown carbapenem resistant Klebsiella 
spp. The patient’s condition improved after treatment with colistin. We came to the 
conclusion that this might be a false positive DFA result. This false positivity could be 
due to misidentification of background fluorescence as trophic forms of P.jirovecii 
(11). 
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6.4.2 DFA negative qPCR positive results: 
i. In Probable PCP group: 
In probable PCP group, qPCR was positive in four out of 20 patients. All the four 
patients were HIV infected. Three of them had typical presentation of PCP and 
showed clinical improvement after treatment. One was a newly diagnosed HIV 
patient, with classic symptoms of PCP, who improved after intravenous co-
trimoxazole. However he expired three days later due to multi organ dysfunction. 
Therefore these patients could be considered as definite PCP. 
ii. In Non-PCP group: 
In our study, one sample from non-PCP group showed positive result by qPCR with a 
copy number of 530/ml. This sample was collected from a nephrology patient who 
was on methyl prednisolone Rapid Progressive Glomerulo Nephritis (RPGN). The 
patient had fever, cough with minimal expectoration and no dyspnoea. High 
Resolution Computed Tomography (HRCT) findings were suggestive of PCP or 
Cytomegalo virus (CMV) and his BAL was positive for CMV. The patient improved 
with anti-viral therapy alone. We concluded that this could be a colonization, as there 
are no classic signs and symptoms of PCP as well as that low copy numbers were 
detected by qPCR. 
6.5 Overall sensitivity and specificity of qPCR against EORTC criteria: 
We have categorized the patients into three groups based on EORTC criteria. 
Hence the sensitivity, specificity were calculated by combining definite and probable 
PCP as a diseased group and non-PCP as a non-diseased group. In our study, qPCR 
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has sensitivity and specificity of 28%, and 98.67% respectively in the diseased group. 
As we have included ‘probable PCP’ into the diseased group, we observed low 
sensitivity compared to other studies (16,58,59,62) 
  Among nine HIV infected patients in the probable PCP group, four of them 
were positive by qPCR. Rest of the patients were on HAART as well as their CD4 
counts are less than 200/mm3. One patient was on therapeutic doses of co-trimoxazole 
for two days before the collection of sample. Other patients were on co-trimoxazole 
prophylaxis, which might be the reason for negative result. 
Among eleven non-HIV infected patients in probable PCP group, six patients 
had classic symptoms and improved with co-trimoxazole treatment. Rest of the five 
patients were treated with multiple antibiotics as well as co-trimoxazole for atypical 
pneumonia. Two among them improved and two patient died due to acute respiratory 
distress syndrome. One patient was discharged against medical advice for worsening 
condition. As PCP was one of the differentials in these five patients we have included 
them in probable PCP group. 
The factors which reduce the sensitivity of PCP diagnostic tests are type of 
sample (invasive or non-invasive), and Co-trimoxazole prophylaxis or treatment 
before collection of sample. As suggested by many authors, induced sputum has low 
number of organisms compared to BAL. But Alanio et al found that there are no 
significant difference in the yield in different samples i.e both induced sputum and 
BAL had same yield by their qPCR assay. 
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6.6  Cost effectiveness analysis: 
The cost effectiveness analysis done with the help of Accounts department in our 
Institution, revealed that qPCR assay is cheaper than DFA. These findings are similar 
to other studies done by Mani Revathy et al and Harris et al (60,64). 
 Mani Revathy et al compared three techniques i.e microscopy using GMS 
staining, qPCR targeting KEX-1 gene and a conventional PCR targeting mtLSUrRNA 
followed by sequencing. They found that qPCR is a simple, highly sensitive and cost 
effective technique (60).  
Harris et al did a cost effective analysis for all the diagnostic options for PCP 
such as, chest X-ray, Diff-Quik, Toludine blue O (TBO), Calcofluor white, GMS, 
DFA, PCR, nested PCR, and qPCR. They observed PCR methodologies are most 
sensitive and cost effective diagnostic option for PCP (64).  
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7. Limitations of the study: 
 
       The cut off value to discriminate active PCP infection from colonization was not 
estimated since the sample size was low. Moreover in our study only one patient was 
identified to have colonization (530 copies/ml). We need to perform a larger study in 
asymptomatic immunocompromised patients to differentiate between active infections 
from colonisation.  
The sensitivity of our microscopy and DFA is low compared to other studies. 
We used only a single sample for testing. Narasimha et al study showed increased 
sensitivity of microscopy when three consecutive induced sputum samples were tested 
and compared to a single sample (70% vs 15%) (65). This could be applied to improve 
sensitivity for non-invasive samples such as induced sputum and endo tracheal 
aspirate (ETA). But the same principle cannot be applied for invasive sample such as 
Broncho alveolar lavage (BAL). 
         Moreover  Doucette S et al described that BAL had a better sensitivity of 90% 
when compared to induced sputum in HIV patients (66). Since the sample size was 
low as well as low incidence of HIV in our centre, we could not ascertain the best 
sample for PCP diagnosis in our study. 
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8. Conclusion: 
 
 This study has evaluated a real-time quantitative PCR assay (qPCR) for routine 
diagnosis of Pneumocystis pneumonia (PCP) in a microbiology laboratory. 
 When compared with clinical classification by EORTC criteria, we observed 
qPCR had 60% positivity in definite PCP and 20% positivity in probable PCP.  
 Overall sensitivity and specificity of DFA and qPCR in clinically suspected 
cases were 20%, 100% and 28%, 98.67% respectively. Though qPCR 
sensitivity is higher than DFA, it was not statistically significant.  
 The sensitivity and specificity of qPCR when compared to DFA was 60% and 
94.74%. 
 The qPCR was negative in two of the five DFA positive samples, where one of 
the sample was found to be false positive by clinical correlation. In addition to 
three DFA positive samples, qPCR also detected four cases in probable group 
which proves that qPCR is superior to DFA.  
 Cost effective analysis revealed that qPCR is cheaper than DFA test.  
 We conclude that real time quantitative PCR assay (qPCR) can replace 
conventional microscopy as a routine diagnostic test for PCP. 
 Larger studies need to be done to evaluate whether single or multiple non-
invasive samples or BAL would yield a better result on qPCR. 
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10.  Annexure 
  
 
  
 
  
 
  
 
 
 
 
                             PATIENT INFORMATION SHEET   
    
Study title: Evaluation of a real-time quantitative PCR for diagnosis of Pneumocystis 
jirovecii pneumonia in immunocompromised patients. 
                                                                                   
Please read this carefully. It tells you important information about the study. A member of the 
research team will explain to you about taking part in this study.  If you have any questions 
about the research or about this form, please ask us. If you decide to take part in this study, 
you must sign or provide your thumb impression in this form to show that you want to take 
part.  
 
Why is this study being done? 
Pneumocystis pneumonia is a disease commonly seen in patients with low immunity; E.g. 
patients with HIV infection and cancer patients on treatment. The tests currently available for 
diagnosing this organism causing this lung infection is not very good in picking up all 
patients with this disease  . So treatment is given to these patients based on clinical 
presentation, not on laboratory tests. This study will help us to diagnose the disease more 
accurately. The respiratory sample that has been sent for routine diagnosis of your disease 
will also be used to evaluate this new test. 
 What will happen in this study? 
The respiratory sample that you have provided for testing will also be used for this new test. 
Will I be paid to take part in this study? 
We will not pay you for providing your sample for research.     
What are the risks and possible discomforts from being in this study? 
There are no extra risks as your sample is already being collected to make a diagnosis. We 
are simply using the sample to evaluate the new test. 
What are the possible benefits from being in this study? 
You will not benefit personally from taking part in this study but you will help us to develop 
an accurate diagnostic test for Pneumocystis pneumonia which may benefit you or other 
patients in the future.  
If I take part in this research study, how will you protect my privacy? 
Information about you collected for this research study will be stored in the Investigator’s 
research files and will be identified only by a number. Your name and other information that 
might identify you will be recorded with a code number. This means that no one will be able 
to tell which sample is yours. The research consent form you sign may be inspected by 
regulatory agencies or the Institutional Review Board in the course of carrying their duties. If 
the signed research consent form is inspected or copied, the Hospital will use reasonable 
efforts to protect your privacy. 
 
If I have questions or concerns about this research study, whom can I call? 
You can call us with your questions or concerns and the details are as below 
1. Dr.S.Dhanalakshmi, 
        PG Registrar, 
        Department of Microbiology, 
        Christian Medical College, Vellore - 632 004, 
         Phone: 0416 2282588, 98650 66752. 
                                       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                         Informed Consent Form for Subjects 
 
Informed Consent form to participate in a research study  
 
Study Title: Evaluation of a real-time quantitative PCR for diagnosis of Pneumocystis 
jirovecii pneumonia in immunocompromised patients. 
 
Study Number: ____________ 
 
 Subject’s Name: _________________________________________ 
 
Date of Birth / Age: ___________________________ 
 
 
 
(i)  I confirm that I have read and understood the information sheet dated ____________ 
for the above study and have had the opportunity to ask questions.  
(ii)  I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care or legal 
rights being affected.  
(iii)  I understand that the Sponsor of the clinical trial, others working on the Sponsor’s 
behalf, the Ethics Committee and the regulatory authorities will not need my permission 
to look at my health records both in respect of the current study and any further research 
that may be conducted in relation to it, even if I withdraw from the trial. I agree to this 
access. However, I understand that my identity will not be revealed in any information 
released to third parties or published.  
(iv)  I agree not to restrict the use of any data or results that arise from this study provided 
such a use is only for scientific purpose(s). 
(v)  I agree to take part in the above study.  
 
 
 
 Signature (or Thumb impression) of the Subject/Legally Acceptable  
Date: _____/_____/______ 
Signatory’s Name: _________________________________         Signature:  
 
Or 
 
 
 
 
 
Representative: _________________ 
 
Date: _____/_____/______ 
 
Signatory’s Name: ________________________________ 
 
Signature of the Investigator: ________________________ 
 
Date: _____/_____/______ 
 
Study Investigator’s Name: _________________________ 
 
 
Signature of the Witness: ___________________________ 
 
Date: _____/_____/_______ 
 
Name and Address of the Witness: ______________________________ 
  
 
Informed Consent Form for Subjects 
Informed Consent form to participate in a research study 
 
Study Title: Evaluation of a real-time quantitative PCR for diagnosis of Pneumocystis 
jirovecii pneumonia in immunocompromised patients.  
Study Number: ____________  
 
Subject’s Name: _________________________________________  
 
Date of Birth / Age: ___________________________  
 
(i)  I confirm that I have read and understood the information sheet dated 
____________ for the above study and have had the opportunity to ask questions.  
(ii) I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care or legal 
rights being affected.  
(iii) I understand that the Sponsor of the clinical trial, others working on the Sponsor’s 
behalf, the Ethics Committee and the regulatory authorities will not need my 
permission to look at my health records both in respect of the current study and 
any further research that may be conducted in relation to it, even if I withdraw 
from the trial. I agree to this access. However, I understand that my identity will 
not be revealed in any information released to third parties or published.  
(iv) I agree not to restrict the use of any data or results that arise from this study 
provided such a use is only for scientific purpose(s).  
(v) I agree to take part in the above study. 
  
Signature (or Thumb impression) of the Subject/Legally Acceptable  
Date: _____/_____/______  
Signatory’s Name: _________________________________ Signature:  
Or  
 
 
 
 
Representative: _________________  
Date: _____/_____/______  
Signatory’s Name: ________________________________  
 
Signature of the Investigator: ________________________  
Date: _____/_____/______  
Study Investigator’s Name: _________________________  
 
Signature of the Witness: ___________________________  
Date: _____/_____/_______  
Name and Address of the Witness: ______________________________ 
 
PCP STUDY PROFORMA 
Patient Information 
 
Study ID: Name: 
Hosp No: Age: Sex  M   /   F 
Date of sample collected: Contact number 
Ph: 
 
Mob: 
Unit: Ward: 
HIV STATUS:     POSITIVE    /    NEGATIVE 
Address: 
 
Clinical profile: 
 
SYMPTOMS SIGNS 
Fever:                          Yes / No Pulse: ______ / minute 
Dry cough:                  Yes / No Blood pressure: _____/_____   mmHg 
Shortness of breath: Yes / No RR: ____ / minute 
Others: Temp: _________    
 PO2: __________ 
  
Radiology 
 
X-ray Suggestive of PCP  Not PCP 
Comments 
 
 
HRCT Suggestive of PCP  Not PCP 
Comments 
 
 
 
Laboratory 
No Test Result 
1 Giemsa stain Positive  Negative 
2 IFA Positive Negative 
3 qPCR assay Positive Negative 
4 CD4 count   
 
Treatment History 
Drug used  
Prophylactic / Curative 
Improvement after treatment Yes No 
Diagnosis at discharge PCP Probable PCP 
Non-PCP  Others 
 
